Apis Assay Technologies Breast Cancer Subtyping Kit

The UK-based company Apis Assay Technologies is launching its Breast Cancer Subtyping Kit as an in vitro diagnostic in the UK and for research use only in other geographies. The RNA-based diagnostic workflow can be used to detect mRNA expression of standard biomarkers (ER, PR, HER2, Ki67) and novel proliferative biomarkers from pre-operative core-needle biopsy or resected FFPE breast tumor tissue. The assay addresses several unmet needs in current practice, including a faster HER2 result turnaround without the need for reflex testing when the IHC result is unclear; higher accuracy of the Ki67 proliferation measurement; and significantly reduced time for results interpretation, the company said. The assay will also be accompanied by validated software for automatic results interpretation, Apis said.